Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Enzon Pharmaceuticals, Inc.
Pharmacokinetic (PK) testing of EZN-2208, will be performed for patients who volunteer. PK testing measures the amount of a drug in the body at different time points.
Age
1–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologic verification of malignancy at original diagnosis or relapse.
Measurable or evaluable disease
Karnofsky score more or equal to 50 for patients \>16 years of age and Lansky score more or equal to 50 for patients \<16 years of age
Patients previously treated with irinotecan will be eligible for this study if they have not had documented progressive disease during treatment with an irinotecan-containing regimen.
Adequate hematologic, hepatic, coagulation, renal, and metabolic function
You may not be if
Pregnant or breast feeding patients will not be enrolled in this study
Patients who are currently receiving other anticancer agents
Patients who have an uncontrolled infection
Patients requiring cytochrome P450 3A4 enzyme inducing or inhibiting agents
Clareo Health | Study of EZN-2208 Pediatric Patients With Solid Tumors
